In Brief
Specific inhibitors of protein Nmyristoylation are powerful probes for exploring the role of this posttranslational modification in cells and have therapeutic potential. Kallemeijn et al. identify three flawed but commonly applied human N-myristoyltransferase inhibitors, and advocate two classes of high-affinity inhibitors as probes with a well-validated on-target cellular mode of action.
INTRODUCTION N-Myristoylation is the irreversible covalent attachment of a saturated 14-carbon myristic acid to the N-terminal glycine of more than 200 proteins in the human proteome (Wright et al., 2010; Lanyon-Hogg et al., 2017; Castrec et al., 2018) . The majority of N-myristoylation occurs co-translationally at the ribosome, where removal of initiator methionine exposes an N-terminal glycine and subsequent recognition sequence (Johnson et al., 1994; Castrec et al., 2018) , while post-translational N-myristoylation may occur following endoproteolysis, for example by caspases during apoptosis, to reveal a de novo N-terminal glycine amenable to modification (Utsumi et al., 2003; Thinon et al., 2014) . In humans, N-myristoylation is catalyzed by two myristoyl-coenzyme A (CoA):protein N-myristoyltransferases (NMTs), NMT1 and NMT2 (Dyda et al., 2000; Giang and Cravatt, 1998; Castrec et al., 2018) , which share $77% sequence identity and have overlapping biological functions and protein substrate selectivity (Giang and Cravatt, 1998; Castrec et al., 2018) . NMT knockout studies in mice have illustrated the importance of N-myristoylation for T cell development and activation (Rampoldi et al., 2012) , and NMT inhibition has been shown to induce ER stress, cell-cycle arrest, and apoptosis in cancer cell lines (Thinon et al., 2016) . N-Myristoylated proteins play a pivotal role in pathological processes underlying infections by viruses and protozoa (Lanyon-Hogg et al., 2017) , with multiple studies validating NMTs as a pharmacological target for the development of antiviral Corbic Ramljak et al., 2018) , antiparasitic (Price et al., 2003; Frearson et al., 2010; Herrera et al., 2016; Wright et al., 2014) , and anti-fungal drugs Weinberg et al., 1995) . A limited set of compounds have been reported as inhibitors of human NMTs, with the most commonly applied being IMP-366 (DDD85646) 1, IMP-1088 2, 2-hydroxymyristic acid 3, D-NMAPPD 4, and Tris-DBA palladium 5 ( Figure 1A ). To date there have been no reports of NMT1/ NMT2-selective inhibitors, likely due to the very high sequence conservation between their catalytic domains. IMP-366 1 (DDD85646) is a nanomolar inhibitor of both recombinant ($20 nM half-maximal inhibitor concentrations [IC 50 ]) and cellular human NMTs . We recently reported that IMP-1088 2, an improved inhibitor ($200 pM K D ) of both NMTs Figure 1A) . At low nanomolar concentrations, 2 completely inhibited N-myristoylation in cells, including that of a rhinoviral capsid protein, thus preventing infectious virus formation . High-resolution X-ray crystal structures further support the high affinity and selectivity of 1 and 2 for human NMT1 and NMT2 Mousnier et al., 2018) . Myristic acid analog 2-hydroxymyristic acid 3 (Figure 1A) was the first compound reported to inhibit NMT in cellular studies (Paige et al., 1989 (Paige et al., , 1990 . At 100 mM to 1 mM, 3 has been reported to reduce metabolic labeling of cells with [ 3 H]myristate (Vaandrager et al., 1996; Tan et al., 2016) and has been suggested to prevent NMT-dependent viral budding (Perez et al., 2004; Du et al., 2010; Tan et al., 2016) . D-NMAPPD 4, also known as B13 ( Figure 1A ), was first reported as an inhibitor for lysosomal acid ceramidase, inducing ceramide-driven apoptosis in melanoma (Bielawska et al., 1996; Raisova et al., 2002) . Recent work, however, has claimed that 4 also inhibits NMT in cells (Kim et al., 2017) , with inhibition hypothesized to depend on the 14-carbon chain shared between 4 and myristoyl-CoA, and by various putative interactions proposed through in silico docking. 4 has a reported biochemical human NMT1 IC 50 of 78 mM which, surprisingly, is ca. 5-fold higher than its reported capacity to reduce N-myristoylation in living cells (IC 50 $15 mM) (Kim et al., 2017) . Tris-DBA palladium 5 ( Figure 1A ) has been described as an NMT inhibitor (Bhandarkar et al., 2008) , although it is more generally used as a catalyst in Suzuki cross-coupling reactions in organic chemistry (Kudo et al., 2006) . 5 has been reported to have anti-tumor activity against A375 melanoma, as exposure of cells to 11 mM 5 resulted in a 96% decrease in cell count (Bhandarkar et al., 2008) . In more recent work, 5 has been shown to cause apoptosis in multiple myeloma (de la Puente et al., 2016) , and to kill chronic lymphocytic leukemia B cells (Kay et al., 2016) and pancreatic cancer cells (Díaz et al., 2016) . The importance of well-characterized, on-target cell-active chemical probes for proteins is widely appreciated across the fields of chemical and cell biology (Arrowsmith et al., 2015; Blagg and Workman, 2017) . Here we report a comprehensive and critical evaluation of the five compounds most prominently claimed and applied as human NMT inhibitors to determine whether they are fit for purpose as chemical probes. We find that compounds 3, 4, and 5 act off-target in all cell lines tested and provide robust evidence that they do not inhibit N-myristoylation in a concentration range consistent with activity on NMT; these data directly contradict prior studies, which have therefore incorrectly applied these compounds as NMT inhibitors. Compounds 1 and 2 were confirmed as the only agents in this panel with potent on-target NMT inhibitory activity in cells, making them the current best-in-class tools for future studies of human N-myristoylation.
RESULTS

Effects on Recombinant Human NMT1 and Cell Line Cytotoxicity
We first examined recombinant human N-myristoyltransferase 1 (rNMT1) inhibition by compounds 1-5, using a standard assay that measures generation of CoA thiol by-product (Figure 1B ). rNMT1 was inhibited in a concentration-dependent manner by 1 and 2, with IC 50 of 29 and 0.24 nM respectively; these values are consistent with previously published data ( Table 1, Goncalves et al., 2012; Mousnier et al., 2018) , although rNMT1 is present at 5 nM in the assay and therefore the IC 50 for 2 cannot be precisely quantified. rNMT1 activity was not reduced by 3 or 4 below 300 mM ( Figure 1B) , with extrapolated IC 50 values higher than those previously reported (Table 1) . Tris-DBA palladium 5 reduced rNMT1 activity in a concentration-dependent manner, with an IC 50 of 4.2 mM. We noted that dilutions of 5 suffered from insolubility in aqueous solutions, as illustrated by black aggregates ( Figure S1A ); absorbance at 750 nm (a measure of degree of precipitation) was determined at various concentrations of 1-5 ( Figure S1B ), revealing that 5 precipitated at 10 mM in large (>750 nm) particles, followed by 3 and 4 at 300 mM. The correlation between reduction of rNMT1 activity and precipitation suggests that NMT inhibition by 3-5 may be partially caused by non-specific interactions with the enzyme. Precipitation of 1 and 2 occurred above 300 mM, 4-6 orders of magnitude above their respective IC 50 values ( Figure 1B) .
Next, we determined cytotoxicity for 1-5 in cell lines of breast (MDA-MB-231) and cervical (HeLa) cancer. Cells were exposed for 24, 48, or 72 h to a range of concentrations in 1-5, followed by nuclei counting as a measure for proliferation, while metabolic activity was assessed using a fluorescent Cell Titer Blue assay using NAD(P)H-dependent cellular oxidoreductase activity to generate an insoluble, fluorescent resorufin product ( Stepanenko and Dmitrenko, 2015) . 1 and 2 affected proliferation of MDA-MB-231 cells only after 48 and 72 h and in a concentration-dependent manner ( Figure 1C ), in line with previously published observations (Thinon et al., 2016; Mousnier et al., 2018) . Proliferation was unaffected by 3, while 30 mM 4 hindered proliferation equally at all time points. In a time-and concentrationdependent manner, 5 potently decreased proliferation with a $300 nM IC 50 . Metabolic activity of MDA-MB-231 cells was affected in line with viability by 1-5 ( Figure S1C ). HeLa cells proved less sensitive to 1-5, but overall trends were analogous to those in MDA-MB-231, both for proliferation and metabolic activity (Figures S1D and S1E, respectively). Tris-DBA palladium 5 precipitated in the media, forming black rod-shaped crystals that adhere to the growth substrate ( Figure 4F ). To investigate whether the crystals were the cytotoxic component, we analyzed the cytotoxicity of 1-5 to Jurkat cells, a T cell leukemia cell line that grows in suspension. Jurkat cells responded to 1, 2, 3, and 4 in a manner highly similar to that in for MDA-MB-231 and HeLa ( Figure S1F ). In sharp contrast, 5 had no effect on metabolic activity in Jurkat, even at the most cytotoxic conditions for MDA-MB-231 and HeLa cells (10 mM 5 for 72 h, Figures  1C and S1E, respectively). The absence of cytotoxicity strongly suggests that 5 kills cells through proximal interactions between adhering cells and crystals.
Effects on N-Myristoylation, NMT Expression, and NMT Substrate ARL1 in Living Cells We next determined the ability of 1-5 to inhibit NMT within living cells by pre-incubation in the presence or absence of DMSO, 1, 2, 3, 4, or 5 for 30 min ( Figure 2A ) followed by metabolic tagging with YnMyr, a myristic acid analog, for 18 h. After lysis, YnMyrtagged proteins were ligated by copper-catalyzed azide-alkyne cycloaddition (CuAAC) to AzTB, a multifunctional reagent containing a TAMRA moiety and a biotin, allowing in-gel visualization by fluorescence ( Figure 2B ). Concentrations of 1-5 were chosen based published data for ca. 100% inhibition of cellular N-myristoylation (1 mM 1; 0.1 mM 2), or concentrations at which compounds at least partially reduced proliferation and metabolic activity (100 mM 3; 30 mM 4; and 10 mM 5). As 1 and 2 had been previously validated using YnMyr methodology (Thinon et al., 2016; Mousnier et al., 2018) , we compared 1 and 2 with 3, 4, and 5 individually on separate gels, in triplicate. Metabolic tagging of N-myristoylated proteins in MDA-MB-231 cells was potently abrogated by 1 and 2, but not by 3-5 ( Figure 2B , full gels in Figure S2A ). HeLa cells responded identically (Figure S3A) . Quantification of YnMyr tagging of ten different bands in both cell lines determined that 3, 4, and 5 provoke at most a minor reduction in YnMyr tagging ( Figure 2C ). Abundance of NMT1 and NMT2 was unaffected by 1-5 in MDA-MB-231 or HeLa cells (Figures 2B and S3A, respectively) . The effect of 1-5 on N-myristoylation of the known NMT substrate ARL1 was investigated by western blotting (Wright et al., 2010; Goya Grocin et al., 2018) . The molecular weight (MW) of ARL1 (20 kDa) increases by 1.3 kDa when YnMyr is ligated by CuAAC to AzTB, resulting in a migratory shift on SDS-PAGE (Figure 2B, bottom) . As expected, in cells exposed to 1 and 2 this higher MW form was absent due to inhibited NMT. Inversely, failure to inhibit cellular NMT by 3-5 was identified through the persistence of the higher MW form of ARL1, with identical observations in HeLa cells ( Figures 2D and S3B ). These results were orthogonally confirmed using a recently reported approach to detect in-cell NMT target engagement without the requirement for metabolic tagging (Figure 2E and Goya Grocin et al., 2018) . Cells were exposed to the previous concentrations of 1-5 for 18 h, and following lysis a biotinylated labeling reagent (Biotin-ALPET-Haa peptide) was ligated by sortase A to the N-terminal glycine of proteins, including non-myristoylated NMT substrates formed as a result of inhibition. Addition of this peptide results in an MW increase of 0.8 kDa; the presence of this higher MW form of ARL1 occurred when N-myristoylation was inhibited by 1 and 2, while 3, 4, and 5 had no effect in MDA-MB-231 cells ( Figure 2F ) or in HeLa cells ( Figure 2G , blots in Figure S3C ). It should be noted that neither YnMyr tagging nor sortase A labeling result in full conversion of ARL1 to the labeled form; this does not indicate incomplete N-myristoylation or incomplete inhibition but rather is due to substoichiometric incorporation of YnMyr and incomplete sortase A reactivity, as previously reported Goya Grocin et al., 2018) .
Next, we expanded sortase A analysis to a broad panel of nine cell lines in which previous studies have reported using 3, 4, or 5 as putative NMT inhibitors ( Figure S2D ). In line with the aforementioned above, 3 did not inhibit NMT in Jurkat, HEK293, and NCI-H23 cells (Nadler et al., 1993; Vaandrager et al., 1996; Liang et al., 2015) , 4 had no effect on MEF, PC-3, and NIH3T3 cells (Kim et al., 2017; Li et al., 2018) , and 5 was cytotoxic in the absence NMT inhibition in A375, NCI-H929, and PANC1 cells (Bhandarkar et al., 2008; de la Puente et al., 2016; Díaz et al., 2016) . However, both 1 and 2 engaged NMT in all cell lines tested ( Figure S2D ).
Effects on the Global N-Myristoylated Proteome in Living Cells
We next used quantitative chemical proteomics to identify changes in NMT substrates provoked by compounds 1-5. HeLa and MDA-MB-231 cells were exposed (in triplicate) to 1-5, in a setup identical to that used for in-gel analyses (Figure 2A) , with the exception that YnMyr-tagged proteins were ligated to AzRB. Labeled proteins were enriched on NeutrAvidin-agarose and digested on-resin with trypsin; peptides were labeled with tandem mass tag, and analyzed and quantified by nano-liquid chromatography-tandem mass Bhandarkar et al., 2008. spectrometry on a Thermo Q-Exactive instrument. Inspection of volcano plots comparing fold change and significance of N-myristoylated proteins identified in MDA-MB-231 (n = 75, Figure S4A ) and HeLa (n = 55, Figure S4B ) reveals that 1 and 2 significantly inhibited N-myristoylation of the majority of NMT substrate proteins identified, in sharp contrast to 3, 4, and 5, which had no impact on N-myristoylation ( Figure 3A) , confirming the in-gel data ( Figure 2C ) quantitatively at the whole-proteome level. Co-translationally N-myristoylated proteins showed variable rates of depletion during NMT inhibition by 1 and 2. A myriad of factors contributes to NMT substrate sensitivities, including the affinity of the substrate protein and NMT, the de novo synthesis rate, rate of initiator methionine removal by methionine aminopeptidases, subcellular localization, and complex interactions at the ribosome and with other proteins . Proteins with an N-terminal glycine that are not NMT substrates did not change on average compared with the control, suggesting that none of the compounds induced major proteomic changes during the 18 h of exposure ( Figure 3B) . Comparison of the different conditions by hierarchical one-minus Pearson correlation clustering revealed that the enrichment of N-myristoylated proteins in MDA-MB-231 cells exposed to 1 or 2 is very similar to that of control cells not treated with YnMyr ( Figure 3C ). In contrast, the response of enrichment to 3-5 clusters with positive control cells, i.e., YnMyr labeling in the presence of no inhibitor, providing unbiased whole-proteome evidence that 3, 4, and 5 do not affect NMT activity in living cells ( Figure 3C ). Similar hierarchical clustering of the chemical proteomics data obtained Figures S2B and S3B ). Plots based on n = 9, 9, 9, 3, 3, 3, 9, 9, 9, 3, 3, and 3 quantifications in duplicate, each individually corrected to loading control HSP90.
from HeLa suggests that these conclusions are common between cell lines ( Figure S4C ).
Effect on Protein Synthesis, Cell Cycle, and Apoptosis
A reduction in co-translational N-myristoylation may be observed due to a failure in protein synthesis, and it is thus important to cross-validate the impact of inhibitors on protein synthesis. Cells were exposed for 18 h to 1-5 (1 mM 1; 0.1 mM 2; 100 mM 3; 30 mM 4; and 10 mM 5), then washed and incubated for 2 h with the methionine analog L-azidohomoalanine (L-AHA), in the absence or presence of cycloheximide (CHX), an inhibitor of protein synthesis ( Figure 4A ). After lysis, L-AHA-containing proteins were ligated to YnTB and fluorescently labeled proteins resolved by gel electrophoresis ( Figure 4B ). Protein synthesis was not significantly reduced after 18 h with 1, 2, and 3, whereas 4 and 5 provoked a significant 40%-80% decrease in L-AHA labeling, both in MDA-MB-231 and HeLa cells ( Figure 4C ). We next analyzed the effect of 1-5 on the cell cycle, as reduced protein synthesis may severely hamper this process. Both MDA-MB-231 and HeLa were exposed to 1-5 for 18 h, followed by fluorescenceactivated cell sorting (FACS) analysis of DNA content and proliferation to determine the phase of the cell cycle in each cell in the tested population. As shown in Figure 4D , 4 and 5 caused a dramatic loss of cells in S phase, while increasing the populations in G 0/1/2 and M phases, indicating that cells stop proliferating upon exposure to 4 or 5, while 1, 2, and 3 had no impact on the cell cycle at 18 h. The prevalence of apoptosis was assessed next, using in the same cell populations stained for active caspase-3, the executioner protease involved in apoptosis. While 1-4 did not induce apoptosis in MDA-MB-231 cells, 5 increased apoptosis more than 30-fold compared with control ( Figure 4E ). HeLa cells, which are less sensitive to 1-5 compared with MDA-MB-231, showed correspondingly lower depletion of S phase and less induction of apoptosis by 4 and 5 ( Figures S3D and S3E ). Finally, these findings were verified by bright-field microscopy, revealing that cells of both cell lines exposed to 4 contained more rounded apoptotic cells, often with overt apoptotic blebbing ( Figures 4F  and S3F, respectively) . Similarly, the majority of MDA-MB-231
and HeLa cells incubated with 5 exhibited this phenotype, particularly in proximity to black crystalline deposits.
DISCUSSION
Here we have evaluated the suitability as chemical probes of five compounds widely applied to inhibit N-myristoylation within living cells. N-Myristoylation inhibition by IMP-366 1, IMP-1088 2, 2-hydroxymyristic acid 3, D-NMAPPD 4, and Tris-DBA palladium 5 was identified by using a combination of quantitative whole-proteome profiling, recombinant inhibition assays, cytotoxicity, protein synthesis, cell cycling, and apoptosis. Our data show only 1 and 2 are suitable chemical probes for human NMTs, considering their capacity to inhibit recombinant NMTs and within living cells, in the absence of cytotoxicity and precipitation. 2-Hydroxymyristic acid 3 is generally applied at concentrations of 100 mM to 1 mM, whereupon a reduction of N-myristoylation has been described (e.g., Vaandrager et al., 1996; Tan et al., 2016; Corbic Ramljak et al., 2018) . It has been proposed that 3 is activated after cellular uptake by acyl-CoA synthases to form 2-hydroxymyristoyl-CoA, a purportedly more potent inhibitor of NMTs (Paige et al., 1990; Harper et al., 1993) . In our hands, however, addition of 3 at 1 mM, directly or in a mixture with BSA, resulted in precipitation in the medium and cell death (data not shown). Moreover, millimolar lipid concentrations are likely to cause off-target toxicity, as reported for porcine alveolar macrophages (1 mM, Du et al., 2010) . While soluble, 100 mM 3 did not inhibit recombinant NMT1 or inhibit cellular N-myristoylation by a wide range of assays, and thus our data invalidate 3 as an NMT inhibitor. It seems plausible that phenotypes previously induced by 3 operate through effects on lipid metabolism, rather than by inhibition of NMT.
The application of D-NMAPPD 4 as NMT inhibitor warrants further discussion. First developed as an inhibitor for lysosomal acid ceramidase (Bielawska et al., 1996) to induce ceramideprovoked apoptosis as therapeutic strategy for melanoma (Raisova et al., 2002) ( Kim et al., 2017) . We were unable to reproduce the stated NMT IC 50 of 78 mM (Kim et al., 2017) , and exposure of cells to 30 mM 4 did not result in changes in overall N-myristoylation nor a reduction of N-myristoylation in c-Src as measured with chemical proteomics. However, this concentration of 4 caused marked cytotoxicity within 24 h by a mechanism unrelated to NMT inhibition, illustrated by loss of protein synthesis, caspase-3 activation, and loss of metabolic activity. The order-of-magnitude difference between onset of cytotoxicity and the extrapolated IC 50 of 4 toward recombinant NMT1 (>300 mM) further demonstrates that NMT is not a cellular target of 4. The data are consistent with 4 potently targeting lysosomal acid ceramidase, as originally reported in various cancer cell lines at >5 mM 4, increasing ceramide concentrations up to 12-fold and thereby inducing ceramide-driven apoptosis (Raisova et al., 2002) . Our data further invalidate 4 as an NMT inhibitor, including direct evidence for failed target engagement in a selection of cell lines previously reported using 4 as a putative NMT inhibitor. Tris-DBA palladium 5 has been previously applied as an NMT inhibitor both in living cells and in vivo in tumors (Bhandarkar et al., 2008; Díaz et al., 2016) . It has also been claimed that 5 is more selective to NMT1 than NMT2 (0.5 and 1.3 mM, respectively; Rampoldi et al., 2012) . In our analysis, 5 inhibited recombinant rNMT1 with an IC 50 of 4.2 mM, a concentration that coincided with 5 precipitating into crystals, suggesting that 5 obstructs NMT through precipitation and not via specific interactions. Chemical proteomics further revealed that in cells exposed to 10 mM 5, a concentration earlier reported as conditions whereby NMT was inhibited in A375 cells (Bhandarkar et al., 2008) , did not prominently affect N-myristoylation. Indeed, the reduction of N-myristoylated proteins identified by chemical proteomics coincided with a marked loss of overall protein synthesis, cytotoxicity, and a 30-fold increase in apoptosis, none of which are consistent with NMT inhibition at the same time point. We noted precipitation of 5 in the growth media of multiple cell lines, most notably at concentrations over 1 mM where 5 has been suggested to cause NMT-associated cell death (Bhandarkar et al., 2008) . Intriguingly, adherent cells, which would come into proximity with crystals of 5, stopped proliferating and lost metabolic activity within 24 h, while cells in suspension were affected neither by a 10-fold higher concentration of 5 nor by the presence of crystals. These data strongly suggest that the cytotoxic effects of 5 are provoked non-specifically through proximity to crystalline deposits. Recently, 5 was incorporated into nanoparticles to circumvent the poor solubility (Elsey et al., 2019) , However, the fundamental inability of 5 to 90, 90, 90, 30, 30, 30, 90, 90, 90, 30, 30, and 30 inhibit cellular N-myristoylation while inducing marked cytotoxicity and apoptosis invalidates this compound as an NMT inhibitor. IMP-366 1 and IMP-1088 2 represent chemically distinct and well-validated NMT inhibitors with defined binding modes supported by several X-ray co-crystal structures for human NMT1 and NMT2 Mousnier et al., 2018) . This contrasts with 3, 4, and 5, for which no X-ray co-crystal data are available. For both 1 and 2, complete inhibition of in-cell N-myristoylation occurred with concentrations approximately 30-to 100-fold above the IC 50 toward recombinant NMT1, correlating with efficacy and phenotypes observed in previous work . It should be noted that while 1 and 2 are bona fide N-myristoyltransferase inhibitors, our data do not comprehensively exclude additional NMTs are the only cellular targets. To identify the exact target engagement of 1 and 2, inactive controls lacking key interactions with the NMTs should be profiled. However, structure-activity relationship data obtained during the development of 1 and 2 indicate clear on-target effects on NMT (Brand et al., 2012 (Brand et al., , 2014 Mousnier et al., 2018; Bell et al., 2017) . Regardless, complete inhibition of in-cell N-myristoylation within 18 h by 1 and 2 occurred in the absence of cytotoxicity, allowing future investigations on the role and regulation of N-myristoylation in living cells. As noted previously, over shorter time frames preexisting N-myristoylated proteins maintain cell viability even in the presence of complete NMT inhibition, while NMT inhibition induces a time-dependent reduction in proliferation and metabolic activity in cancer cell lines with prolonged exposure at 48 or 72 h.
SIGNIFICANCE
The critical importance of well-characterized, on-target, cell-active chemical probes is widely appreciated across both chemical and cell biology, while invalid probes inevitably lead to misleading or invalid biological conclusions. In this work we present an in-depth evaluation of the specificity of five compounds widely applied as human N-myristoyltransferase (NMT) inhibitors, using a combination of enzymatic assays, quantitative whole-proteome profiling of N-myristoylation, cytotoxicity, in-cell protein synthesis, and cell-cycle assays. The inability of 2-hydroxymyristic acid, D-NMAPPD, and Tris-DBA palladium to inhibit cellular NMT across multiple cell types in the absence of off-target effects and cytotoxicity demonstrates the invalidity of these compounds as NMT inhibitors, and we propose that they should not be used as inhibitors of N-myristoylation. The results of previous studies in which these compounds are used as NMT inhibitors should be reassessed in light of these data. The evidence presented here advocates the application of IMP-366 and IMP-1088 as current best-inclass probes for human NMT, which block cellular N-myristoylation in the absence of off-target cytotoxicity.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Ed Tate (e.tate@imperial.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines were obtained from ATCC and verified by STR by The Francis Crick Cell Services. All cells were cultured in humidified 37 C incubators. Human cervical cancer cell line HeLa (female) and human pancreatic cancer cell line PANC1 (male) were cultured in DMEM with low glucose and 10% (v/v) FCS at a 10% (v/v) CO 2 atmosphere. Human breast cancer cell line MDA-MB-231 (female) was cultured in DMEM with low glucose and 10% (v/v) FCS at a 5% (v/v) CO 2 atmosphere. Human T-cell leukaemia cell line Jurkat (male) was cultured in RPMI with 10% (v/v) FCS at a 5% (v/v) CO 2 atmosphere. Human lung cancer cell line NCI H23 (male), human myeloma cell line H929 (female), human prostate cancer cell line PC-3 (male), human melanoma cell line A375 (female), human embryonic kidney cell line HEK293 (foetal, unknown sex), murine primary embryonic fibroblasts MEF (embryonic, unknown sex) and murine embryonic fibroblast cell line NIH 3T3 (embryonic, unknown sex) were cultured in DMEM with high glucose supplemented with GlutaMAX, 10% (v/v) FCS, HEPES, sodium pyruvate, Penicillin-Streptamycin, NEAA and 2 mL/500 mL of b-mercaptoethanol, at a 5% (v/v) CO 2 atmosphere.
